The partnership of UCB and Biogen announced disappointing news, confirming that its experimental therapy dapirolizumab pegol (DZP) failed to meet its primary endpoint in the treatment...
Indicated for patients who are inadequate responders to existing therapies, Benlysta is approved for use as an add-on therapy in autoantibody-positive SLE patients.